Topics

Human medicines European public assessment report (EPAR): Sifrol, pramipexole, Restless Legs Syndrome,Parkinson Disease, Date of authorisation: 13/10/1997, Revision: 32, Status: Authorised

12:01 EDT 7 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Sifrol, pramipexole, Restless Legs Syndrome,Parkinson Disease, Date of authorisation: 13/10/1997, Revision: 32, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Sifrol, pramipexole, Restless Legs Syndrome,Parkinson Disease, Date of authorisation: 13/10/1997, Revision: 32, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Sifrol, pramipexole, Restless Legs Syndrome,Parkinson Disease, Date of authorisation: 13/10/1997, Revision: 32, Status: Authorised"

Quick Search

Relevant Topics

Sleep Disorders
Sleep disorders disrupt sleep during the night, or cause sleepiness during the day, caused by physiological or psychological factors. The common ones include snoring and sleep apnea, insomnia, parasomnias, sleep paralysis, restless legs syndrome, circa...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...